Frequent promoter hypermethylation of the KEAP1 gene and its control role in down-regulation of gene expression was reported by our group in neoplastic tissues of patients affected by glioma, breast cancer (51%), primary NSCLC (47%), and in many cases, it was associated with a worse overall survival in patients [27,28,30,31]. The gene discussed is KEAP1; the disease is central nervous system cancer.